Lipidor Signs Agreement With CRO for Implementation of Phase III Clinical Study of Drug Candidate AKP-02 Against Psoriasis |
| July 08, 2020 | July 2020 Bond Updates |
|
STOCKHOLM, July 8, 2020 /PRNewswire/ -- Lipidor AB (Nasdaq First North: LIPI) today announced an agreement with Cadila Pharmaceuticals, a leading Indian pharmaceutical company with extensive CRO capacity, to conduct a Phase III study for Lipidor's drug candidate AKP-02. The study is... |
| View more at: https://www.prnewswire.com:443/news-releases/lipidor-signs-agreement-with-cro-for-implementation-of-phase-iii-clinical-study-of-drug-candidate-akp-02-against-psoriasis-301089831.html |
| Related News |